Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma

Abstract Tumor mutational burden (TMB) is an emerging predictive marker of response to immune checkpoint inhibitor therapies. We evaluated the correlation between clinical indicators and high‐throughput sequencing results and TMB in lung adenocarcinoma patients, with the aim of finding simpler and m...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Kai Ma, Fengxiang Huang, Yin Wang, Yan Kang, Qilong Wang, Jiaqi Tang, Panfeng Sun, Jiaojiao Lou, Ruiping Qiao, Jiming Si, Jian Cao, Lijun Miao
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2022-11-01
Ráidu:	Cancer Medicine
Fáttát:	immune checkpoint inhibitors lung adenocarcinoma tumor mutational burden (TMB)
Liŋkkat:	https://doi.org/10.1002/cam4.4781
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!